US biopharmaceutical company Scolr, latterly known as Nutraceutix, is to ship the first order for its patented controlled delivery product Glucosamine/Chondroitin to Europe.
The first-to-market European customer, Springfield Nutraceuticals, based in the Netherlands, provides science-based nutritional products.
"Springfield intends to roll out the unique CDT Glucosamine/Chondroitin all over Europe through selective partners, such as well established wholesalers and drugstore chains. SCOLR's CDTControlled Delivery Technology, combined with glucosamine/chondroitin, offers a great advantage over the competition and will strengthen our position as an innovative supplier of nutraceuticals," said Peter van Hogerhuis, general manager of Springfield.
Glucosamine is a BCS (Biopharmaceutical Classification Scheme) class 1 ingredient. Both glucosamine and chondroitin are used to help diminish the joint damaging effects of osteoarthritis.
This first European commercialisation of our patented CDT technology will help to generate early revenue streams from dietary supplement products - which will provide some support for the significant longer-term investments necessary to bring a prescription drug utilising our CDT technology to market after 2005, " said David Howard, president and CEO of Scolr